Healthy men to test copycat cancer drug in early trial
NCT ID NCT07495930
First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called HLX319 against an approved cancer drug (EU-Phesgo®) in 24 healthy Chinese men. The goal is to see how the body processes each drug and check for side effects. Participants receive a single injection and are monitored closely. This trial does not treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Medical University Second Affiliated Hospital
Hefei, Anhui, 230601, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.